Subtotal $0.00
CJC-1295 is a synthetic peptide designed to act like growth hormone-releasing hormone (GHRH), the hormone that signals the pituitary gland to release growth hormone. It is not FDA-approved for any use, and no approved medicine in the United States contains it.
It is built on GRF(1-29), the first 29 amino acids of human GHRH, the same active section used in sermorelin. Four of those amino acids were swapped to make the peptide more resistant to breakdown in the blood, and a chemical linker was attached at one end.
The linker is known as DAC (Drug Affinity Complex). It lets the peptide attach to albumin, a common blood protein, once it is in the body. Binding to albumin greatly slows its removal: in a 2006 study in healthy adults, the estimated half-life of CJC-1295 was about 6 to 8 days.
The name CJC-1295 is used loosely online. Products sold as "CJC-1295 without DAC," "CJC-1295 no DAC" or "Modified GRF (1-29)" (often shortened to "mod GRF 1-29") are generally described as the same four-substitution GRF(1-29) peptide without the albumin-binding linker. That makes them a different molecule that stays in the body for a much shorter time. The clinical studies described below tested the DAC version and do not describe the no-DAC peptide.
CJC-1295 was developed by ConjuChem, a biotechnology company in Montreal, Canada. A 2005 study in rats, published in Endocrinology, identified it as the most stable and longest-lasting of several albumin-binding GRF(1-29) designs the company tested.
In 2006, researchers reported two randomized, placebo-controlled, double-blind trials in healthy adults aged 21 to 61 in the Journal of Clinical Endocrinology and Metabolism. The trials measured blood levels of growth hormone and IGF-1 over 28 and 49 days. After a single administration, average growth hormone levels rose 2- to 10-fold for 6 days or more, and IGF-1 levels rose 1.5- to 3-fold for 9 to 11 days. No serious adverse reactions were reported.
These were short, early-phase studies of hormone levels, not trials of health outcomes. CJC-1295 was never developed into an approved medicine, and there is no published evidence that it is safe or effective for any condition in people.
Current status: Not FDA-approved.
CJC-1295 has not gone through the FDA review that a drug must pass before it can be marketed for use in people.
CJC-1295 was previously on the FDA's Category 2 list of bulk substances that raise significant safety concerns for compounding. The FDA cited a possible risk of immunogenicity (an unwanted immune response), difficulties with peptide impurities, and serious adverse events it had identified, including increased heart rate and a systemic vasodilatory reaction (widening of blood vessels throughout the body).
As of the FDA's April 2026 update, CJC-1295 is listed among substances whose nominations were withdrawn by the nominators and that are no longer in Category 2. That change did not add CJC-1295 to the list of substances pharmacies may use for compounding, and it was not among the peptides reviewed by the FDA's Pharmacy Compounding Advisory Committee in July 2026.
Products sold online as research chemicals or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or quality.
The World Anti-Doping Agency (WADA) 2026 Prohibited List names CJC-1295 as an example of a GHRH analog under class S2. It is prohibited at all times, in and out of competition.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply CJC-1295, and we do not point readers to anyone who does.
For personal medical questions, including questions about CJC-1295, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. Related profiles: sermorelin, ipamorelin and the CJC-1295 and ipamorelin blend. We compare the GHRH analogs and ipamorelin in tesamorelin vs sermorelin.
Shop Now
